Global vaccine innovation in
Asia-Pacific

With 46% of global prophylactic vaccine trials and 31% of therapeutic trials conducted in the Asia-Pacific region, the region has emerged as a global leader in vaccine research and development. A collaborative ecosystem, cutting-edge technology advancements, and strategic investments have led to this dominance. Vaccines, traditionally seen as the foundation of public health for their role in preventing infectious diseases, are now transcending their original purpose. They are exploring new therapeutic possibilities for chronic and complex conditions, marking a transformative shift in the industry. Novotech’s 2024 whitepaper, Vaccine Clinical Trial Global Landscape, underscores these shifts, providing a detailed analysis of how innovation and regional dynamics are reshaping the vaccine landscape. The report highlights both the robustness of prophylactic vaccines and the burgeoning potential of therapeutic vaccines, particularly in oncology and chronic infections. Transforming prophylaxis into therapy For decades, vaccines have been synonymous with disease prevention. Yet, the industry is now turning toward therapeutic...